This HTML5 document contains 43 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
dctermshttp://purl.org/dc/terms/
n9http://linked.opendata.cz/resource/domain/vavai/riv/tvurce/
n18http://linked.opendata.cz/resource/domain/vavai/subjekt/
n11http://linked.opendata.cz/ontology/domain/vavai/
shttp://schema.org/
rdfshttp://www.w3.org/2000/01/rdf-schema#
skoshttp://www.w3.org/2004/02/skos/core#
n3http://linked.opendata.cz/ontology/domain/vavai/riv/
n2http://linked.opendata.cz/resource/domain/vavai/vysledek/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n10http://linked.opendata.cz/resource/domain/vavai/vysledek/RIV%2F00064165%3A_____%2F13%3A10195716%21RIV14-MZ0-00064165/
n6http://linked.opendata.cz/ontology/domain/vavai/riv/klicoveSlovo/
n8http://linked.opendata.cz/ontology/domain/vavai/riv/duvernostUdaju/
xsdhhttp://www.w3.org/2001/XMLSchema#
n17http://linked.opendata.cz/ontology/domain/vavai/riv/aktivita/
n14http://linked.opendata.cz/ontology/domain/vavai/riv/jazykVysledku/
n16http://linked.opendata.cz/ontology/domain/vavai/riv/druhVysledku/
n7http://linked.opendata.cz/ontology/domain/vavai/riv/obor/
n4http://reference.data.gov.uk/id/gregorian-year/

Statements

Subject Item
n2:RIV%2F00064165%3A_____%2F13%3A10195716%21RIV14-MZ0-00064165
rdf:type
n11:Vysledek skos:Concept
rdfs:seeAlso
http://fb.cuni.cz/file/5667/FB2013A0002.pdf
dcterms:description
Anti-VEGF therapy dramatically improved the outcome of patients with renal cancer and other advanced malignancies, but may be complicated by proteinuria and hypertension. VEGF is indispensable for the normal development of glomerulus and preservation of glomerular filtration barrier. Interference with its action may result in damage to glomerular endothelial cells and (in severe cases) in renal thrombotic microangiopathy. Blood pressure and proteinuria (using dipstick) should be assessed in all patients before starting anti-VEGF therapy and regularly monitored during the treatment. Patients with severe proteinuria and/or impaired renal function should be referred to the nephrologist for further work-up. Hypertension caused by anti-VEGF therapy can be effectively treated; progression of proteinuria and/or renal dysfunction may require tapering, or even withdrawal of anti-VEGF treatment. Anti-VEGF therapy dramatically improved the outcome of patients with renal cancer and other advanced malignancies, but may be complicated by proteinuria and hypertension. VEGF is indispensable for the normal development of glomerulus and preservation of glomerular filtration barrier. Interference with its action may result in damage to glomerular endothelial cells and (in severe cases) in renal thrombotic microangiopathy. Blood pressure and proteinuria (using dipstick) should be assessed in all patients before starting anti-VEGF therapy and regularly monitored during the treatment. Patients with severe proteinuria and/or impaired renal function should be referred to the nephrologist for further work-up. Hypertension caused by anti-VEGF therapy can be effectively treated; progression of proteinuria and/or renal dysfunction may require tapering, or even withdrawal of anti-VEGF treatment.
dcterms:title
Proteinuria and Hypertension in Patients Treated with Inhibitors of the VEGF Signalling Pathway - Incidence, Mechanisms and Management Proteinuria and Hypertension in Patients Treated with Inhibitors of the VEGF Signalling Pathway - Incidence, Mechanisms and Management
skos:prefLabel
Proteinuria and Hypertension in Patients Treated with Inhibitors of the VEGF Signalling Pathway - Incidence, Mechanisms and Management Proteinuria and Hypertension in Patients Treated with Inhibitors of the VEGF Signalling Pathway - Incidence, Mechanisms and Management
skos:notation
RIV/00064165:_____/13:10195716!RIV14-MZ0-00064165
n11:predkladatel
n18:ico%3A00064165
n3:aktivita
n17:I
n3:aktivity
I
n3:cisloPeriodika
1
n3:dodaniDat
n4:2014
n3:domaciTvurceVysledku
n9:6812473 n9:5909627
n3:druhVysledku
n16:J
n3:duvernostUdaju
n8:S
n3:entitaPredkladatele
n10:predkladatel
n3:idSjednocenehoVysledku
100530
n3:idVysledku
RIV/00064165:_____/13:10195716
n3:jazykVysledku
n14:eng
n3:klicovaSlova
sorafenib; sunitinib; bevacizumab; hypertension; proteinuria; VEGF inhibition
n3:klicoveSlovo
n6:proteinuria n6:VEGF%20inhibition n6:sorafenib n6:sunitinib n6:bevacizumab n6:hypertension
n3:kodStatuVydavatele
CZ - Česká republika
n3:kontrolniKodProRIV
[2F36CC0BE1AA]
n3:nazevZdroje
Folia Biologica
n3:obor
n7:FD
n3:pocetDomacichTvurcuVysledku
2
n3:pocetTvurcuVysledku
2
n3:rokUplatneniVysledku
n4:2013
n3:svazekPeriodika
59
n3:tvurceVysledku
Tesařová, Petra Tesař, Vladimír
n3:wos
000326215200002
s:issn
0015-5500
s:numberOfPages
11